Business UpdateMay 15, 2026, 08:13 AM
Waldencast's Obagi Medical Shares Positive Clinical Data for Skincare
AI Summary
Waldencast's Obagi Medical announced new clinical and real-world data for its NU-GEN Cellular Renewal Serum and Obagi Saypha® MagIQ™ dermal filler at the Music City SCALE meeting. The NU-GEN serum showed clinical proof of visibly rewinding skin's age by up to six years. Interim real-world data for the Saypha® MagIQ™ filler indicated that 94% of injectors found it complementary to existing options, with 43% of patients also evaluating Obagi skincare.
Key Highlights
- Obagi NU-GEN Cellular Renewal Serum clinically proven to visibly rewind skin's age by up to six years.
- Interim real-world data for Obagi Saypha® MagIQ™ dermal filler presented from over 300 participating sites.
- 94% of injectors believe Obagi Saypha® MagIQ™ complements their current filler options.
- 43% of patients evaluating Obagi Saypha® MagIQ™ also evaluated Obagi skincare.
- The ALOHA Program is anticipated to become the largest real-world evaluation program for a new injectable filler.
Price Impact
More from WALD